These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 215096)

  • 1. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction.
    Jasinski DR; Pevnick JS; Griffith JD
    Arch Gen Psychiatry; 1978 Apr; 35(4):501-16. PubMed ID: 215096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts.
    Fudala PJ; Yu E; Macfadden W; Boardman C; Chiang CN
    Drug Alcohol Depend; 1998 Mar; 50(1):1-8. PubMed ID: 9589267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nalbuphine.
    Schmidt WK; Tam SW; Shotzberger GS; Smith DH; Clark R; Vernier VG
    Drug Alcohol Depend; 1985 Feb; 14(3-4):339-62. PubMed ID: 2986929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buprenorphine and naloxone interactions in methadone maintenance patients.
    Mendelson J; Jones RT; Welm S; Brown J; Batki SL
    Biol Psychiatry; 1997 Jun; 41(11):1095-101. PubMed ID: 9146820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Buprenorphine.
    Lewis JW
    Drug Alcohol Depend; 1985 Feb; 14(3-4):363-72. PubMed ID: 2986930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs. methadone.
    Seifert J; Metzner C; Paetzold W; Borsutzky M; Passie T; Rollnik J; Wiese B; Emrich HM; Schneider U
    Pharmacopsychiatry; 2002 Sep; 35(5):159-64. PubMed ID: 12237786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etorphine in man. I. Subjective effects and suppression of morphine abstinence.
    Jasinski DR; Griffith JD; Carr CB
    Clin Pharmacol Ther; 1975 Mar; 17(3):267-72. PubMed ID: 1091396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone.
    Rosado J; Walsh SL; Bigelow GE; Strain EC
    Drug Alcohol Depend; 2007 Oct; 90(2-3):261-9. PubMed ID: 17517480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.
    Correia CJ; Walsh SL; Bigelow GE; Strain EC
    Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buprenorphine: a review of its pharmacological properties and therapeutic efficacy.
    Heel RC; Brogden RN; Speight TM; Avery GS
    Drugs; 1979 Feb; 17(2):81-110. PubMed ID: 378645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buprenorphine versus morphine. A comparison of intra-operative and postoperative analgesia.
    Green DW; Sinclair JR; Mikhael MS
    Anaesthesia; 1985 Apr; 40(4):371-5. PubMed ID: 3890604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Buprenorphine and morphine efficacy in postoperative pain: a double-blind multiple-dose study.
    Ouellette RD
    J Clin Pharmacol; 1982 Apr; 22(4):165-72. PubMed ID: 7047580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence.
    Ling W; Wesson DR; Charuvastra C; Klett CJ
    Arch Gen Psychiatry; 1996 May; 53(5):401-7. PubMed ID: 8624183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients.
    Eissenberg T; Johnson RE; Bigelow GE; Walsh SL; Liebson IA; Strain EC; Stitzer ML
    Drug Alcohol Depend; 1997 Apr; 45(1-2):81-91. PubMed ID: 9179510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade with methadone, cyclazocine, and naloxone.
    Freedman AM; Zaks A; Resnick R; Fink M
    Int J Addict; 1970 Sep; 5(3):507-15. PubMed ID: 5524385
    [No Abstract]   [Full Text] [Related]  

  • 16. [Abuse of alcohol and benzodiazepine during substitution therapy in heroin addicts: a review of the literature].
    Laqueille X; Launay C; Dervaux A; Kanit M
    Encephale; 2009 Jun; 35(3):220-5. PubMed ID: 19540407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opioid addicts at admission vs. slow-release oral morphine, methadone, and sublingual buprenorphine maintenance treatment participants.
    Giacomuzzi S; Kemmler G; Ertl M; Riemer Y
    Subst Use Misuse; 2006; 41(2):223-44. PubMed ID: 16393744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute interactions of buprenorphine with intravenous cocaine and morphine: an investigational new drug phase I safety evaluation.
    Teoh SK; Mendelson JH; Mello NK; Kuehnle J; Sintavanarong P; Rhoades EM
    J Clin Psychopharmacol; 1993 Apr; 13(2):87-99. PubMed ID: 8463453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Buprenorphine as maintenance treatment in rehabilitation of heroin addicts].
    Bramness JG; Bachs LC; Waal H
    Tidsskr Nor Laegeforen; 2002 Oct; 122(25):2452-4. PubMed ID: 12448114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buprenorphine suppresses heroin use by heroin addicts.
    Mello NK; Mendelson JH
    Science; 1980 Feb; 207(4431):657-9. PubMed ID: 7352279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.